Skip to main content

Table 4 Complications, treatment, and prognosis of patients with COVID-19

From: Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19

Variables All Patients (n = 550) Severe (n = 178) Non-severe (n = 372) p value
Complications n, %
 Acute myocardial injury 111(20.2%) 76(42.7%) 35(9.4%) < 0.001
 Secondary infection 110 (20.0%) 82(46.1%) 28(7.5%) < 0.001
 ARDS 69 (12.5%) 69(38.8%) 0 < 0.001
 Acute kidney injury 45 (8.2%) 33(18.5%) 12(3.2%) < 0.001
 Shock 40 (7.3%) 39(21.9%) 1(0.3%) < 0.001
 DIC 20(3.6%) 11(6.2%) 9(2.4%) 0.028
Treatment n.%
 Antiviral therapy 449 (81.6%) 162(91.0%) 287(77.2%) < 0.001
 Antibacterial therapy
  one kind 204 (37.1%) 40(22.5%) 164(44.1%) < 0.001
   ≥ two kinds 231(42.0%) 136(76.4%) 95(25.5%) < 0.001
 Antifungal therapy 10(1.8%) 8(4.5%) 2(0.5%) 0.004
 Glucocorticoids therapy 191(34.7%) 122(68.5%) 69(18.5%) < 0.001
Immunotherapy
 Human immunoglobulin 52(9.5%) 23(12.9%) 29(7.8%) 0.055
 Thymosin 10(1.8%) 6(3.4%) 4(1.1%) 0.123
Vasoactive drug 34(6.2%) 34(19.1%) 0 < 0.001
 CRRT 2(0.4%) 2(1.1%) 0 0.104
Respiratory support-no.%
 Nasal catheter/Mask oxygen 477(86.8%) 105(59.0%) 372(100.0%) < 0.001
 High-flow nasal cannula 5 (0.9%) 5(2.8%) 0 < 0.001
 Noninvasive ventilation 32 (5.8%) 32(18.0%) 0 < 0.001
 Invasive ventilation 36 (6.5%) 36(20.2%) 0 < 0.001
 ECMO 0 0 0
prognosis-no.%
 Transfer 24 (4.4%) 16 (9.0%) 8 (2.2%) < 0.001
 Improved 474 (86.1%) 110 (61.8%) 364 (97.8%) < 0.001
 Death 52(9.5%) 52(29.2%) 0 < 0.001
     Multiple system and organ failure 33/52 (63.5%) 33/52 (63.5%)
     Respiratory failure 16/52 (30.8%) 16/52 (30.8%)
     Circulatory failure 2/52 (3.8%) 2/52 (3.8%)
     Septic shock 1/52 (1.9%) 1/52 (1.9%)
Negative conversion time of RNA Detection, Median (IQR)-days 10 (6–16) 13 (8–18) 9 (6–16) 0.016
Length of hospital stay, Median (IQR)-days 16 (9–26) 22 (13–30) 15 (9–22.75) < 0.001